<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056614</url>
  </required_header>
  <id_info>
    <org_study_id>1913.00</org_study_id>
    <secondary_id>NCI-2009-01785</secondary_id>
    <secondary_id>1913.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P01HL036444</secondary_id>
    <nct_id>NCT01056614</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies</brief_title>
  <official_title>Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying the side effects and how well giving fludarabine phosphate,
      busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant,
      tacrolimus, and methotrexate works in treating patients with myeloid malignancies. Giving
      chemotherapy, such as fludarabine phosphate and busulfan, before a donor peripheral blood
      stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's
      immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor
      are infused into the patient they may help the patient's bone marrow make stem cells, red
      blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor
      can make an immune response against the body's normal cells. Giving anti-thymocyte globulin
      before transplant and tacrolimus and methotrexate after transplant may stop this from
      happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. Determine the incidence and severity of acute graft-versus-host disease (GvHD).

      SECONDARY OBJECTIVES:

      I. Determine the pharmacokinetics of intravenous (IV) busulfan including interdose
      variability and evaluation of a limited sampling strategy.

      II. Determine thymoglobulin (anti-thymocyte globulin) pharmacokinetics.

      III. Determine the incidence of donor engraftment.

      IV. Determine system toxicities &gt;= grade 3 per Common Terminology Criteria for Adverse Events
      (CTCAE) version (v.) 3.

      V. Determine the incidence and severity of chronic GvHD.

      VI. Determine the incidence of non-relapse mortality at day +100 and at 1 year (yr).

      VII. Determine the incidence of relapse.

      VIII. Determine relapse-free survival.

      IX. Determine the incidence of Epstein-Barr virus (EBV) activation.

      OUTLINE:

      Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days -9 to -6,
      busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on
      days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic peripheral blood stem
      cell (PBSC) transplant on day 0. Patients then receive tacrolimus IV continuously or orally
      (PO) every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1,
      3, 6, and 11.

      After completion of study treatment, patients are followed at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GvHD</measure>
    <time_frame>Day 100 post-transplant</time_frame>
    <description>Maximum grade of acute GVHD and the number of therapies required to treat GVHD will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of IV busulfan including interdose variability and evaluation of a limited sampling strategy</measure>
    <time_frame>At 3.25, 4.5, 6, 8, 11, and 24-hours after the beginning of infusion on days -5, -4, and -3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thymoglobulin pharmacokinetics</measure>
    <time_frame>On day -3 prior to the first dose, on day -1 one hour after completion of infusion and on day 1 at 0900</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of donor cell engraftment</measure>
    <time_frame>By day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of system toxicities &gt;= grade 3 as graded per CTCAE v.3</measure>
    <time_frame>Up to day 100 after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GvHD</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality defined as death without history of post-transplant relapse</measure>
    <time_frame>At day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality defined as death without history of post-transplant relapse</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year</time_frame>
    <description>Defined by either morphological or cytogenetic evidence of chronic myelogenous leukemia (CML), AML, MDS or other myeloproliferative disease in marrow, blood, or other sites, or laboratory evidence of residual disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of EBV activation defined as an increase in plasma EBV DNA to &gt;= 1000 copies/mL as determined by quantitative polymerase chain reaction (PCR)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV and orally</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, PBSC transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic myelogenous leukemia in chronic phase, accelerated phase and treated blast
             phase (CP2)

          -  Acute myeloid leukemia (AML) in remission or early relapse (&lt; 10% marrow blasts)

          -  Myelodysplastic syndromes (MDS) ( all risk groups)

          -  Other myeloproliferative disorders

          -  DONOR: related or unrelated donors matched for human leukocyte antigen (HLA)-A, B, C,
             DRB1, and DQB1 defined by high resolution deoxyribonucleic acid (DNA) typing or
             mismatched for a single HLA-A, B, C, DRB1 or DQB1 allele

          -  DONOR: donor must consent to peripheral blood stem cell (PBSC) mobilization with
             granulocyte colony-stimulating factor (G-CSF) and leukapheresis; related donors will
             be collected at Fred Hutchinson Cancer Research Center (FHCRC), while unrelated donors
             will be collected through the National Marrow Donor Program (NMDP) or other donor
             centers

          -  DONOR: Age 12-75 yrs

        Exclusion Criteria:

          -  Cardiac insufficiency requiring treatment or symptomatic coronary artery disease

          -  Hepatic disease, with aspartate aminotransferase (AST) &gt; 2 times normal

          -  Severe hypoxemia, oxygen partial pressure (pO2) &lt; 70 mm Hg, with decreased diffusion
             capacity of carbon monoxide (DLCO) &lt; 70% of predicted; or mild hypoxemia, pO2 &lt; 80 mm
             Hg with severely decreased DLCO &lt; 60% of predicted

          -  Impaired renal function (creatinine &gt; 2 times normal or estimated creatinine clearance
             &lt; 60 ml/min)

               -  MALE: ([140 -age in years] x ideal body weight [kg])/72 x serum creatinine (SCr)
                  (mg/dL)

               -  FEMALE: .85 x ([140-age in years] x ideal body weight [kg])/72 x SCr (mg/dL)

          -  Human immunodeficiency virus (HIV)-positive patients due to risk of reactivation or
             acceleration of HIV replication

          -  Female patients who are pregnant or breast feeding

          -  Life expectancy severely limited by diseases other than malignancy

          -  DONOR: donors who for any reason are unable to tolerate the mobilization and
             leukapheresis procedure

          -  DONOR: donors who are HIV-positive, or hepatitis B or C antigen-positive

          -  DONOR: female donors who have a positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

